Bicocca Open Archive

Logo unimib boa
CAZZANIGA, MARINA ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.530
EU - Europa 3.739
AS - Asia 2.270
SA - Sud America 107
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 12.673
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.453
IT - Italia 1.216
SG - Singapore 1.101
DE - Germania 631
IE - Irlanda 502
HK - Hong Kong 446
SE - Svezia 397
RU - Federazione Russa 392
CN - Cina 387
ID - Indonesia 150
UA - Ucraina 123
GB - Regno Unito 117
BR - Brasile 95
AT - Austria 87
CA - Canada 70
FI - Finlandia 62
IN - India 61
DK - Danimarca 53
NL - Olanda 46
VN - Vietnam 45
FR - Francia 38
TR - Turchia 23
BE - Belgio 14
ES - Italia 13
JP - Giappone 9
IR - Iran 8
PK - Pakistan 7
RO - Romania 7
CH - Svizzera 6
CL - Cile 5
CZ - Repubblica Ceca 5
SC - Seychelles 5
ZA - Sudafrica 5
AL - Albania 4
AR - Argentina 4
EU - Europa 4
KR - Corea 4
LT - Lituania 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
AU - Australia 3
BD - Bangladesh 3
BG - Bulgaria 3
MA - Marocco 3
MX - Messico 3
PH - Filippine 3
UZ - Uzbekistan 3
A1 - Anonimo 2
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BY - Bielorussia 2
KZ - Kazakistan 2
LV - Lettonia 2
MT - Malta 2
MU - Mauritius 2
PL - Polonia 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BO - Bolivia 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
ET - Etiopia 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
KE - Kenya 1
LI - Liechtenstein 1
MD - Moldavia 1
ME - Montenegro 1
MM - Myanmar 1
MN - Mongolia 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
TW - Taiwan 1
UY - Uruguay 1
Totale 12.673
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.733
Singapore 744
Fairfield 506
Dublin 490
Frankfurt am Main 461
Hong Kong 442
Milan 412
Chandler 367
Wilmington 344
Woodbridge 305
Ashburn 301
Houston 247
New York 235
Santa Clara 218
Seattle 197
Cambridge 183
Princeton 160
Jakarta 145
Jacksonville 109
Dearborn 86
Lawrence 74
Altamura 72
Vienna 64
Shanghai 58
San Diego 52
Chicago 44
Guangzhou 41
Beijing 40
Helsinki 39
Rome 38
London 36
Nanjing 34
Andover 33
Boardman 32
Council Bluffs 28
Nuremberg 28
Dong Ket 27
Lissone 22
Falls Church 21
Toronto 21
Monza 19
Pune 19
Desio 18
Kocaeli 17
Hebei 16
Los Angeles 16
Ottawa 15
Brussels 14
Lachine 14
Tianjin 14
Carate Brianza 13
Florence 13
Hangzhou 13
Jinan 13
Edmonton 12
Turin 11
Munich 10
Nanchang 10
Norwalk 10
Paris 10
Zhengzhou 10
Amsterdam 9
Kunming 8
Lappeenranta 8
Mumbai 8
Redmond 8
Romola 8
Shenyang 8
Cinisello Balsamo 7
Potenza 7
Seregno 7
Shenzhen 7
Chengdu 6
Dallas 6
Hyderabad 6
Lecco 6
Madrid 6
Modena 6
Moscow 6
Naples 6
Palermo 6
Peschiera Borromeo 6
Torre Del Greco 6
Washington 6
Wuhan 6
Atlanta 5
Bergamo 5
Bologna 5
Capaccio 5
Casorate Primo 5
Cassano Magnago 5
Changsha 5
Ferrara 5
Fremont 5
Gallarate 5
Genoa 5
Hounslow 5
Islington 5
Legnano 5
Mariano Comense 5
Totale 9.014
Salva come PNG Salva come JPEG
Nome #
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 424
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 318
A Multidisciplinary Intervention to Tell Children about the Parent's Cancer: Preliminary Results 316
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 257
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 252
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 248
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 247
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 241
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 235
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study 228
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 221
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 219
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 211
A second update on mapping the human genetic architecture of COVID-19 209
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 205
Mapping the human genetic architecture of COVID-19 196
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract 192
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 191
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 191
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 186
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 178
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 169
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 166
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 157
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 155
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 154
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 151
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 150
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 150
When progressive dysphagia could be related to an “old friend” – a case report 150
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 150
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y) 148
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 138
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 133
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 132
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 126
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 124
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 122
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 122
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 121
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 121
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 120
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project 118
NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer 117
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 116
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 116
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 110
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 110
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project 109
A multidisciplinary approach to screen the post-COVID-19 conditions 108
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 108
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 107
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE 106
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 106
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? 105
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 102
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 97
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study 91
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 91
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era 87
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring 86
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? 82
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 82
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 82
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers 81
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 77
Adjuvant systemic treatment of early breast cancer: the NORA study 75
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 75
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 74
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 72
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 70
The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study 70
Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: Management considerations 69
In reply to Kadri Altundag 69
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 68
Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study 68
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 66
5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study 65
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 64
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study 64
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 63
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study 61
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: A multi-cycle, phase II study 60
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 59
Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists? 59
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 58
Everolimus plus exemestane in advanced breast cancer: Safety results of the BALLET study on patients previously treatedwithout and with chemotherapy in the metastatic setting 58
Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials 57
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab 57
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 56
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 56
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 56
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 53
Metronomic chemotherapy for advanced breast cancer patients 51
Metronomic chemotherapy 51
Breast cancer in elderly women: a different reality? Results from the NORA study 50
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) 50
Gene expression profiling in breast cancer: a clinical perspective 49
Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study 49
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: Current status and future development 48
Totale 12.388
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.014
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020282 0 0 0 0 0 0 0 0 0 124 128 30
2020/20212.513 71 208 212 204 184 236 223 359 240 210 175 191
2021/20221.198 126 121 150 87 49 90 62 89 58 75 85 206
2022/20232.106 252 550 162 154 121 268 135 140 100 62 87 75
2023/20241.945 89 75 67 93 255 397 354 57 171 56 65 266
2024/20253.363 260 748 412 263 373 265 308 171 561 2 0 0
Totale 13.404